Which has stronger valuation & earnings, RMD or MEDP?

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 6.33 $1.40B $10.37 21.67 Medpace $2.53B 6.41 $451.12M $17.06 34.08

Is RMD or MEDP more profitable?

ResMed has a net margin of 27.44% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Medpace 17.67% 110.15% 24.84%

Does the media prefer RMD or MEDP?

In the previous week, Medpace had 1 more articles in the media than ResMed. MarketBeat recorded 12 mentions for Medpace and 11 mentions for ResMed. Medpace's average media sentiment score of 1.23 beat ResMed's score of 0.97 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RMD or EHC more profitable?

ResMed has a net margin of 27.44% compared to Encompass Health's net margin of 10.04%. ResMed's return on equity of 25.35% beat Encompass Health's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Encompass Health 10.04% 18.28% 8.27%

Does the media refer more to RMD or EHC?

In the previous week, Encompass Health had 2 more articles in the media than ResMed. MarketBeat recorded 13 mentions for Encompass Health and 11 mentions for ResMed. Encompass Health's average media sentiment score of 1.10 beat ResMed's score of 0.97 indicating that Encompass Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Encompass Health 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, RMD or HIMS?

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 6.33 $1.40B $10.37 21.67 Hims & Hers Health $2.37B 2.93 $128.37M -$0.09 N/A

Is RMD or HIMS more profitable?

ResMed has a net margin of 27.44% compared to Hims & Hers Health's net margin of -0.56%. ResMed's return on equity of 25.35% beat Hims & Hers Health's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Hims & Hers Health -0.56% 6.10% 1.52%

Does the media refer more to RMD or HIMS?

In the previous week, Hims & Hers Health had 10 more articles in the media than ResMed. MarketBeat recorded 21 mentions for Hims & Hers Health and 11 mentions for ResMed. ResMed's average media sentiment score of 0.97 beat Hims & Hers Health's score of 0.28 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 4 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, RMD or MDT?

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 6.33 $1.40B $10.37 21.67 Medtronic $36.36B 3.03 $4.80B $3.73 23.08

Is RMD or MDT more profitable?

ResMed has a net margin of 27.44% compared to Medtronic's net margin of 13.20%. ResMed's return on equity of 25.35% beat Medtronic's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Medtronic 13.20% 14.51% 7.76%

Does the media favor RMD or MDT?

In the previous week, Medtronic had 14 more articles in the media than ResMed. MarketBeat recorded 25 mentions for Medtronic and 11 mentions for ResMed. ResMed's average media sentiment score of 0.97 beat Medtronic's score of 0.72 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Medtronic 13 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive

Which has preferable earnings & valuation, BSX or RMD?

Boston Scientific has higher revenue and earnings than ResMed. Boston Scientific is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boston Scientific $20.07B 3.58 $2.90B $2.47 20.09 ResMed $5.15B 6.33 $1.40B $10.37 21.67

Is BSX or RMD more profitable?

ResMed has a net margin of 27.44% compared to Boston Scientific's net margin of 17.50%. ResMed's return on equity of 25.35% beat Boston Scientific's return on equity. Company Net Margins Return on Equity Return on Assets Boston Scientific 17.50% 19.28% 10.89% ResMed 27.44% 25.35% 18.69%

Does the media favor BSX or RMD?

In the previous week, Boston Scientific had 25 more articles in the media than ResMed. MarketBeat recorded 36 mentions for Boston Scientific and 11 mentions for ResMed. ResMed's average media sentiment score of 0.97 beat Boston Scientific's score of 0.88 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 21 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Live Earnings Conference Call: ResMed will host a live Q4 2026 earnings call on August 6, 2026 at 4:30PM ET. Get details.

ResMed (RMD) Competitors

$224.67 +0.64 (+0.28%)

As of 02:28 PM Eastern

Compare

RMD vs. MEDP, EHC, HIMS, MDT, and BSX

Should you buy ResMed stock or one of its competitors? MarketBeat compares ResMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ResMed include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Medtronic (MDT), and Boston Scientific (BSX).

How does ResMed compare to Medpace?

ResMed (NYSE:RMD) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

ResMed has a net margin of 27.44% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Medpace	17.67%	110.15%	24.84%

ResMed currently has a consensus target price of $246.25, suggesting a potential upside of 9.61%. Medpace has a consensus target price of $584.18, suggesting a potential upside of 0.48%. Given ResMed's stronger consensus rating and higher possible upside, analysts clearly believe ResMed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15

In the previous week, Medpace had 1 more articles in the media than ResMed. MarketBeat recorded 12 mentions for Medpace and 11 mentions for ResMed. Medpace's average media sentiment score of 1.23 beat ResMed's score of 0.97 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	10 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

55.0% of ResMed shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.7% of ResMed shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	6.33	$1.40B	$10.37	21.67
Medpace	$2.53B	6.41	$451.12M	$17.06	34.08

Summary

Medpace beats ResMed on 10 of the 16 factors compared between the two stocks.

How does ResMed compare to Encompass Health?

ResMed (NYSE:RMD) and Encompass Health (NYSE:EHC) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.1%. Encompass Health pays an annual dividend of $0.84 per share and has a dividend yield of 0.7%. ResMed pays out 23.1% of its earnings in the form of a dividend. Encompass Health pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 13 consecutive years and Encompass Health has raised its dividend for 2 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

ResMed has higher earnings, but lower revenue than Encompass Health. Encompass Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	6.33	$1.40B	$10.37	21.67
Encompass Health	$6.07B	2.06	$566.20M	$5.99	20.99

55.0% of ResMed shares are held by institutional investors. Comparatively, 97.3% of Encompass Health shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 1.8% of Encompass Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ResMed has a net margin of 27.44% compared to Encompass Health's net margin of 10.04%. ResMed's return on equity of 25.35% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Encompass Health	10.04%	18.28%	8.27%

In the previous week, Encompass Health had 2 more articles in the media than ResMed. MarketBeat recorded 13 mentions for Encompass Health and 11 mentions for ResMed. Encompass Health's average media sentiment score of 1.10 beat ResMed's score of 0.97 indicating that Encompass Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Encompass Health	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed currently has a consensus target price of $246.25, indicating a potential upside of 9.61%. Encompass Health has a consensus target price of $144.43, indicating a potential upside of 14.89%. Given Encompass Health's stronger consensus rating and higher possible upside, analysts plainly believe Encompass Health is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
Encompass Health	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89

ResMed has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Encompass Health has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

Summary

ResMed beats Encompass Health on 11 of the 20 factors compared between the two stocks.

How does ResMed compare to Hims & Hers Health?

ResMed (NYSE:RMD) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

ResMed has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.4, indicating that its share price is 140% more volatile than the broader market.

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	6.33	$1.40B	$10.37	21.67
Hims & Hers Health	$2.37B	2.93	$128.37M	-$0.09	N/A

55.0% of ResMed shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 0.7% of ResMed shares are owned by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Hims & Hers Health had 10 more articles in the media than ResMed. MarketBeat recorded 21 mentions for Hims & Hers Health and 11 mentions for ResMed. ResMed's average media sentiment score of 0.97 beat Hims & Hers Health's score of 0.28 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	4 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

ResMed has a net margin of 27.44% compared to Hims & Hers Health's net margin of -0.56%. ResMed's return on equity of 25.35% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Hims & Hers Health	-0.56%	6.10%	1.52%

ResMed currently has a consensus price target of $246.25, indicating a potential upside of 9.61%. Hims & Hers Health has a consensus price target of $31.43, indicating a potential upside of 4.94%. Given ResMed's stronger consensus rating and higher possible upside, equities analysts clearly believe ResMed is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Summary

ResMed beats Hims & Hers Health on 12 of the 16 factors compared between the two stocks.

How does ResMed compare to Medtronic?

ResMed (NYSE:RMD) and Medtronic (NYSE:MDT) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

In the previous week, Medtronic had 14 more articles in the media than ResMed. MarketBeat recorded 25 mentions for Medtronic and 11 mentions for ResMed. ResMed's average media sentiment score of 0.97 beat Medtronic's score of 0.72 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Medtronic	13 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	6.33	$1.40B	$10.37	21.67
Medtronic	$36.36B	3.03	$4.80B	$3.73	23.08

ResMed has a net margin of 27.44% compared to Medtronic's net margin of 13.20%. ResMed's return on equity of 25.35% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Medtronic	13.20%	14.51%	7.76%

ResMed has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

ResMed presently has a consensus target price of $246.25, indicating a potential upside of 9.61%. Medtronic has a consensus target price of $98.83, indicating a potential upside of 14.80%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
Medtronic	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67

55.0% of ResMed shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 0.3% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.1%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.3%. ResMed pays out 23.1% of its earnings in the form of a dividend. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ResMed has raised its dividend for 13 consecutive years and Medtronic has raised its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Medtronic beats ResMed on 10 of the 19 factors compared between the two stocks.

How does ResMed compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Boston Scientific has higher revenue and earnings than ResMed. Boston Scientific is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.58	$2.90B	$2.47	20.09
ResMed	$5.15B	6.33	$1.40B	$10.37	21.67

In the previous week, Boston Scientific had 25 more articles in the media than ResMed. MarketBeat recorded 36 mentions for Boston Scientific and 11 mentions for ResMed. ResMed's average media sentiment score of 0.97 beat Boston Scientific's score of 0.88 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	21 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has a net margin of 27.44% compared to Boston Scientific's net margin of 17.50%. ResMed's return on equity of 25.35% beat Boston Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.50%	19.28%	10.89%
ResMed	27.44%	25.35%	18.69%

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Boston Scientific presently has a consensus target price of $71.62, indicating a potential upside of 44.30%. ResMed has a consensus target price of $246.25, indicating a potential upside of 9.61%. Given Boston Scientific's stronger consensus rating and higher probable upside, research analysts plainly believe Boston Scientific is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.71
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

Boston Scientific has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, ResMed has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Summary

ResMed beats Boston Scientific on 9 of the 16 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RMD vs. The Competition

Export

Metric	ResMed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$32.57B	$5.72B	$6.90B	$24.04B
Dividend Yield	1.08%	1.78%	2.60%	3.70%
P/E Ratio	21.65	24.63	281.40	32.00
Price / Sales	6.33	59.72	571.91	165.52
Price / Cash	19.92	32.67	71.79	32.36
Price / Book	5.52	6.05	12.86	6.88
Net Income	$1.40B	$152.55M	$3.49B	$1.07B
7 Day Performance	7.68%	3.25%	2.49%	1.88%
1 Month Performance	2.87%	-1.83%	-2.82%	1.47%
1 Year Performance	-19.83%	9.26%	75.72%	19.41%

ResMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RMD ResMed	4.6554 of 5 stars	$224.67 +0.3%	$246.25 +9.6%	-21.3%	$32.57B	$5.15B	21.65	10,600
MEDP Medpace	2.8959 of 5 stars	$589.37 -2.0%	$560.92 -4.8%	+34.7%	$16.79B	$2.53B	34.55	6,200	Positive News
EHC Encompass Health	4.3109 of 5 stars	$113.77 +0.8%	$143.86 +26.4%	-3.2%	$11.20B	$5.94B	18.99	42,000	News Coverage Positive News Earnings Report Analyst Forecast Gap Up
HIMS Hims & Hers Health	2.3623 of 5 stars	$30.23 +7.6%	$31.43 +4.0%	-42.9%	$6.50B	$2.35B	N/A	2,442	Upcoming Earnings
MDT Medtronic	4.8687 of 5 stars	$84.29 +1.3%	$98.21 +16.5%	-4.1%	$106.51B	$36.36B	22.60	95,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RMD) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Competitors

RMD vs. MEDP, EHC, HIMS, MDT, and BSX

How does ResMed compare to Medpace?

Summary

How does ResMed compare to Encompass Health?

Summary

How does ResMed compare to Hims & Hers Health?

Summary

How does ResMed compare to Medtronic?

Summary

How does ResMed compare to Boston Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RMD vs. The Competition

ResMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ResMed (RMD) Competitors

RMD vs. MEDP, EHC, HIMS, MDT, and BSX

How does ResMed compare to Medpace?

Is RMD or MEDP more profitable?

Do analysts prefer RMD or MEDP?

Does the media prefer RMD or MEDP?

Which has more volatility & risk, RMD or MEDP?

Do insiders & institutionals hold more shares of RMD or MEDP?

Which has stronger valuation & earnings, RMD or MEDP?

Summary

How does ResMed compare to Encompass Health?

Is RMD or EHC a better dividend stock?

Which has preferable valuation and earnings, RMD or EHC?

Do institutionals & insiders have more ownership in RMD or EHC?

Is RMD or EHC more profitable?

Does the media refer more to RMD or EHC?

Do analysts recommend RMD or EHC?

Which has more risk and volatility, RMD or EHC?

Summary

How does ResMed compare to Hims & Hers Health?

Which has more volatility & risk, RMD or HIMS?

Which has preferable valuation & earnings, RMD or HIMS?

Do insiders and institutionals have more ownership in RMD or HIMS?

Does the media refer more to RMD or HIMS?

Is RMD or HIMS more profitable?

Do analysts rate RMD or HIMS?

Summary

How does ResMed compare to Medtronic?

Does the media favor RMD or MDT?

Which has higher earnings and valuation, RMD or MDT?

Is RMD or MDT more profitable?

Which has more volatility and risk, RMD or MDT?

Do analysts prefer RMD or MDT?

Do insiders & institutionals have more ownership in RMD or MDT?

Is RMD or MDT a better dividend stock?

Summary

How does ResMed compare to Boston Scientific?

Which has preferable earnings & valuation, BSX or RMD?

Does the media favor BSX or RMD?

Is BSX or RMD more profitable?

Do insiders & institutionals believe in BSX or RMD?

Do analysts prefer BSX or RMD?

Which has more risk & volatility, BSX or RMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RMD vs. The Competition

ResMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools